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Introduction: Adenocarcinoma of the lung, especially bronchi-
oloalveolar carcinoma (BAC) and adenocarcinoma with BAC fea-
tures (AWBF), is potentially sensitive to epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs); however, the ef-
ficacy seems to differ between the histologic subtypes. Mucinous
BAC and AWBF (MBAC/AWBF) are not particularly responsive to
EGFR-TKIs compared with nonmucinous BAC/AWBF (N-MBAC/
AWBF). This may be due to the rarity of EGFR mutations and high
frequency of KRAS mutations in MBAC/AWBF in contrast to
N-MBAC/AWBF.
Methods: One hundred ninety-one patients with adenocarcinoma of
the lung underwent surgery at our institution. There were 59 patients
(30%) diagnosed with BAC/AWBF; 20 had MBAC/AWBF (10%)
and 39 had N-MBAC/AWBF (20%). We isolated 44 tissue speci-
mens from these patients (20 consecutive cases of MBAC/AWBFs
and 24 randomly chosen cases of N-MBAC/AWBFs as the control
group), and we analyzed them for EGFR and KRAS mutations. We
used the peptide nucleic acid-locked nucleic acid polymerase chain
reaction clump method to detect EGFR mutations and conventional
DNA sequencing to identify KRAS mutations.
Results: EGFR mutations were found in three of the 20 MBAC/
AWBFs (15%) and in 14 of the 24 N-MBAC/AWBFs (58%) (p 
0.005). In addition, there were 14 KRAS mutations identified in the
20 MBAC/AWBFs (70%) and seven in the 24 N-MBAC/AWBFs
(29%) (p  0.0144).
Conclusions: The incidence of EGFR mutation is low and that of
KRAS mutation is frequent in MBAC/AWBFs. Conversely, the
incidence of EGFR mutation is high and KRAS mutation is low in
N-MBAC/AWBFs. Based on these findings, EGFR-TKIs may not be
effective in patients with MBAC/AWBF.
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Many recent reports have demonstrated the efficacy ofepidermal growth factor receptor-tyrosine kinase inhib-
itors (EGFR-TKIs) (erlotinib1 or gefitinib2) in treating recur-
rent non-small cell lung cancer. Early investigations on
EGFR-TKIs indicated that there are several clinicopatholog-
ical factors that predict a good response outcome including
gender (female); smoking status (never smoker); ethnicity
(east Asian); and histology (adenocarcinoma).3,4 These drugs
can achieve a remarkably high response in patients who meet
all of these criteria. These patients tend to have somatic
EGFR gene mutations, which is associated with a good
EGFR-TKI response rate.5,6 The presence of an EGFR mu-
tation has been well established as one of the strongest
predictive factors of EGFR-TKI efficacy.
In contrast, KRAS mutation has been indicated as a
predictive factor of a poor outcome for EGFR-TKI treat-
ment.7 This mutation, which is strongly associated with a
history of smoking, is detected in approximately 5 to 30% of
lung adenocarcinomas.8,9 The incidence of KRAS mutation is
different among ethnicities, similarly to that observed for
EGFR mutations. In whites, 20 to 30% of adenocarcinomas
of the lung harbor mutations in KRAS,8 whereas it ranges
from 5 to 20% in Asians.9
Bronchioloalveolar carcinoma (BAC) is defined as: “an
adenocarcinoma variant that grows along pre-existing alveo-
lar structures with a pure lepidic growth pattern and without
evidence of stromal, vascular or pleural invasion and subdi-
vided into nonmucinous, mucinous or mixed type,” according
to the revised World Health Organization international his-
tologic classification of 1999.10 According to this classifica-
tion, BAC is defined as an in situ noninvasive proliferation of
bronchioloalveolar cells and is a rare entity. Because the
BAC component of the proliferation is not mostly homoge-
nous and the lesion is partially noninvasive, it develops as an
adenocarcinoma with BAC features (AWBF) that are usually
predominant.11 Adenocarcinoma, especially BAC and AWBF
(BAC/AWBF), has been demonstrated to be sensitive to
EGFR-TKIs.3,12 In addition, it has been suggested that a
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pathologic subtype with a BAC component is predictive of
the presence of an EGFR mutation.13 However, the efficacy
of EGFR-TKIs seems to differ between the histologic sub-
types. It has been reported that mucinous BAC and AWBF
(MBAC/AWBFs) are not particularly responsive to EGFR-
TKIs compared with nonmucinous BAC and AWBF (N-
MBAC/AWBFs).14 A potential reason for this differential
response may be the rarity of EGFR mutations and frequency
of KRAS mutations in MBAC/AWBFs compared with N-
MBAC/AWBFs. Marchetti et al.15 and other studies16–18 pre-
viously documented that BAC/AWBF with a mucinous com-
ponent is associated with the absence of EGFR mutations and
presence of KRAS mutations. Multiple studies have analyzed
EGFR mutations in BAC/AWBF; however, these studies did
not distinguish between MBAC/AWBF and N-MBAC/
AWBF, so there is insufficient data regarding the incidence of
mutations in these subtypes.
In this study, we examined the incidence of EGFR and
KRAS mutations in MBAC/AWBF specimens, which were
surgically obtained and histologically confirmed. N-MBAC/
AWBF specimens were also concomitantly examined to com-




One hundred and ninety-one patients with adenocarci-
noma of the lung underwent surgical lung resection at our
institution between January 2004 and October 2007. Of these
patients, 59 (30%) were diagnosed with BAC/AWBF; 20 had
MBAC/AWBF (10%); and 39 had N-MBAC/AWBF (20%).
We isolated and analyzed 44 BAC/AWBF specimens from
these patients (20 consecutive cases of MBAC/AWBFs and
24 randomly chosen cases of N-MBAC/AWBFs as the control
group). All the MBACs were not pure BAC; they were
AWBFs. As for the N-MBAC cases, seven of the 15 stage Ia
N-MBACs were identified as pure BAC. The other eight
stage Ia N-MBACs and more advanced cases were all
AWBFs. In terms of the MBACs, AWBFs significantly
predominated over pure BAC, in comparison with the N-
MBAC cases (p  0.0111). Patients who reported never
smoking in their lifetime were defined as “never smoker.”
Those who had smoked within 1 year of the diagnosis were
categorized as “current smoker.” The rest were considered
former smokers. We obtained approval for our study from our
hospital’s Institutional Review Board, and informed consent
was obtained from all study participants.
EGFR and KRAS Gene Mutation Analysis
We isolated DNAs from formalin-fixed paraffin-em-
bedded surgical specimens. Tumor samples were mapped
using hematoxylin-eosin stains, manually microdissected
with a needle, and subjected to DNA isolation. EGFR muta-
tions within exon 18 to 21 were examined using the peptide
nucleic acid-locked nucleic acid polymerase chain reaction
clump method established by Nagai et al.19 in 2005. KRAS
mutations in codons 12 and 13 of exon 2 were analyzed using
conventional DNA sequencing.
Statistical Analysis
The Fisher exact test was performed to analyze the
associations between EGFR or KRAS mutations and the




Patient characteristics are provided in Table 1. In terms
of gender and smoking history, female and never smoker
were dominant characteristics in the N-MBAC/AWBF group
compared with the MBAC/AWBF group. Regarding the
pathologic stage, MBAC/AWBFs tended to be more advanced
than N-MBAC/AWBFs.
We evaluated the response in patients who had been
treated with gefitinib, according to the RECIST. There were five
recurrent patients in the MBAC/AWBF group. Gefitinib was
administered to one patient with a KRAS mutation and no
concomitant EGFR mutation, and she did not respond to ge-
fitinib at all. In contrast, only two of 24 patients with N-MBAC/
AWBF patients experienced recurrence after surgery. Gefitinib was
administered to both of these patients and partial responses were
achieved. One patients with N-MBAC/AWBF was administered
gefitinib before surgery, and this patient also obtained a partial
response. All three of these patients had EGFR mutations.
EGFR and KRAS Mutational Analysis
We were able to analyze the EGFR and KRAS muta-
tional status in 20 MBAC/AWBF and 24 N-MBAC/AWBF
surgical specimens. EGFR mutations were identified in three
of the 20 MBAC/AWBFs (15%). In contrast, EGFR mutations
were detected in 14 of the 24 N-MBAC/AWBFs (58%). EGFR
mutations were less observed in MBAC/AWBFs compared with
N-MBAC/AWBFs (p  0.005) (Table 2). There were 12 KRAS
mutations in 20 of the MBAC/AWBFs (70%) and seven KRAS
mutations in 24 of the N-MBAC/AWBFs (29%). KRAS muta-
tions were more frequently observed in MBAC/AWBFs than in
N-MBAC/AWBFs (P  0.0144) (Table 2).
TABLE 1. Patient Characteristics
Subtypes Mucinous (n  20) Nonmucinous (n  24)
Median age (range) 71 (51–81) 65 (43–81)
Gender (%)
Male 9 (45) 5 (21)
Female 11 (55) 19 (79)
Smoking history (%)
Never 10 (50) 18 (76)
Former 2 (10) 3 (12)
Current 8 (40) 3 (12)
Pathological stage (%)
Ia 2 (10) 15 (63)
Ib 10 (50) 4 (17)
IIa 1 (5) 0 (0)
IIb 0 (0) 1 (4)
IIIa 3 (15) 3 (12)
IIIb 4 (20) 1 (4)
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Three patients with MBAC/AWBF had concomitant
EGFR and KRAS mutations. EGFR and KRAS mutations
were not mutually exclusive in this study population.
Types and Frequencies of EGFR and KRAS
Mutations
The most frequent EGFR mutation was detected in
exon 21 (L858R) (10 patients [59%]), followed by exon 19
(deletion) (seven patients [41%]). Only one mutation in exon
18 (G719C) (6%) was found. One patient had concomitant
mutations in both exon 19 (deletion) and exon 21 (L858R). In
terms of KRAS mutation, the GGT (glycine) in codon 12 was
changed to GAT (aspartic acid) in 14 cases (67%), to GTT
(valine) in five cases (24%), to TGT (cysteine) in one case
(5%), and to GCT (alanine) in one case (5%).
The specific mutations in the three patients with con-
comitant EGFR and KRAS mutations were as follows: exon
19 (deletion) and exon 21 (L858R) of EGFR, and a G to A
transition mutation of KRAS; exon 19 (deletion) of EGFR and
a G to A transition mutation of KRAS; and exon 21 (L858R)
of EGFR and a G to A transition mutation of KRAS.
Associations between EGFR or KRAS and
Clinical Factors
Associations between EGFR or KRAS mutations and
clinical factors, such as age (65 versus 65), gender,
smoking status (never smoker versus ever smoker), and
clinical stage (stage I versus stages II and III), were analyzed
by univariate analysis. Although all factors were not signif-
icantly related, there was a marginal association between
KRAS and gender (p  0.0516).
We also examined the relationship between the types of
KRAS mutation and smoking status. In 14 patients with a
KRAS transition mutation (GGT to GAT), eight were never
smokers, and the others were ever smokers. In those patients
with a transversion mutation (GGT to GTT), three were never
smokers and two were ever smokers. Each patient with a
GGT to TGT or a GGT to GCT was a never smoker.
DISCUSSION
Our findings indicate that the incidence of EGFR mu-
tation is low and KRASmutation is frequent in MBAC/AWBF
compared with N-MBAC/AWBF. A few previous studies
have reported similar results (Table 3). Some studies per-
formed on non-Japanese populations stated that there were no
EGFR mutations in MBAC/AWBF cases. However, two Jap-
anese studies (Sakuma et al.18 and our study) reported that
EGFR mutations are not commonly detected in MBAC/
AWBF but can exist. In terms of the incidence of KRAS
mutations in MBAC/AWBFs, each study reported a mutation
frequency ranging from 67 to 86%, which was consistent
with that observed in our study.
Some previous studies showed that EGFR-TKIs were
effective in treating BAC/AWBFs, but these studies did not
distinguish between MBAC/AWBFs and N-MBAC/AWBFs.3,12
Administration of EGFR-TKIs for patients with BAC/AWBF
may not result in a good response if the subtypes are not
considered before treatment. As has been well established,
EGFR mutation is a predictive factor of a good response and
KRAS mutation is a predictive factor of a poor response to
EGFR-TKIs due to resistance. Our results predict that we may
not be able to obtain a positive response to EGFR-TKIs in
MBAC/AWBF patients in contrast to patients with N-MBAC/
AWBF. This prediction is supported by the results of the SWOG
0126 study,14 where all 11 patients with MBAC/AWBF exhib-
ited no response to gefitinib and six of the 20 (30%) patients
with N-MBAC/AWBF achieved a partial response. The results
from the IFCT-0401 trial20 indicated a poor survival outcome for
MBAC/AWBF compared with N-MBAC/AWBF. Gefitinib was
administered to four patients in our study: all three N-MBAC/
AWBF patients achieved very good responses, whereas the
patients with MBAC/AWBF had no response; however, three of
the MBAC/AWBF specimens (15%) harbored EGFRmutations,
so MBAC/AWBFs may not always be resistant to EGFR-TKIs.
In fact, only a few case reports from Japan demonstrated that
EGFR-TKIs elicited a response in patients with MBAC/
AWBF.21,22 It has been reported that Japanese (Asians) popula-
tions are more sensitive to EGFR-TKIs than whites.3,4 Such a
difference in the efficacy of EGFR-TKIs in MBAC/AWBFs as a
consequence of ethnicity may thus exist. Hence, Japanese pa-
tients who have MBAC/AWBF may not always be completely
resistant to EGFR-TKIs. Finberg et al.17 reported that EGFR
sequence analysis could be avoided in BAC/AWBF white cases
where there is true mucinous morphology identified to avoid
screening costs. However, our study results suggest that EGFR
mutation analysis should be performed in all Asian MBAC/
AWBF cases, especially in Japanese populations.
Our study has two advantages compared with previous
studies. First, the number of EGFR and KRAS mutational
analysis for MBAC/AWBFs were performed with more spec-
imens than any other previous studies. Overall, our knowl-
TABLE 2. Comparison of the Frequency of EGFR and KRAS
Mutations
Mucinous (%) Nonmucinous (%) p
EGFR
Mutation 3/20 (15) 14/24 (58) 0.005
Wild type 17/20 (85) 10/24 (42)
KRAS
Mutation 14/20 (70) 7/24 (29) 0.0144
Wild type 6/20 (30) 17/24 (71)
EGFR, epidermal growth factor receptor.
TABLE 3. The Frequency of EGFR and KRAS Mutations in
Mucinous Subtype
Study EGFR Mutation (%) KRAS Mutation (%)
Marchetti et al.15 0/17 (0) 13/17 (76)
Tam et al.16 0/5 (0) N.D.
Finberg et al.17 0/13 (0) 6/7 (86)
Sakuma et al.18 2/9 (22) 6/9 (67)
Present study 3/20 (15) 14/20 (70)
Total 5/64 (8) 39/53 (74)
N.D., not determined/not reported; EGFR, epidermal growth factor receptor.
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edge of these cases is still quite limited. If all studies of
MBAC/AWBFs are collectively analyzed, there would only
be 64 cases to survey. Second, all the examined specimens
were surgically obtained. According to the 1999 WHO clas-
sification of adenocarcinoma of the lung, the extension of and
form around the lesion is important for the diagnosis of BAC.
In addition, Travis et al.11 proposed that given the require-
ment for a BAC to show pure lepidic growth without invasion
and the knowledge that most lung adenocarcinomas with a
BAC component also have invasive areas, it is impossible to
make an unequivocal diagnosis of BAC in small biopsy
specimens (acquired from needle or bronchoscopic speci-
mens). Hence, we propose that surgically acquired tissue
specimens are better for BAC diagnosis than small samples
obtained by other biopsy methods.
Three MBAC/AWBF cases had concomitant EGFR and
KRAS mutations in our study. Many studies have reported that
EGFR and KRAS mutations were mutually exclusive.15,23,24
Such double mutations have been previously reported in only a
few cases.18,25,26 Sakuma et al.18 have reported similar double
mutations in two MBAC/AWBF specimens in their study pop-
ulation. Interestingly, all five of the MBAC/AWBF specimens
with double mutations are from Japan; there have been no
double mutations identified in MBAC/AWBF specimens from
other countries. This suggests that ethnicity may affect EGFR
mutation status. Therefore, MBAC/AWBFs with concomitant
EGFR and KRAS mutations may actually exist; however, be-
cause only a few cases have been described, whether such
double mutations indeed exist remains controversial and further
studies in large scale are warranted.
In conclusion, the incidence of EGFR mutation is rare,
and KRAS mutation is frequent in MBAC/AWBFs compared
with N-MBAC/AWBFs. Therefore, before EGFR-TKIs are
administered to patients with BAC/AWBF, we should con-
sider the difference of subtypes. Of course, we should analyze
EGFR mutational status for such patients if it is possible.
There have only been a small number of studies distinguish-
ing MBAC/AWBFs from N-MBAC/AWBFs, so further vali-
dation studies are warranted.
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